43 related articles for article (PubMed ID: 20337729)
21. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2009 Mar; 181(3):1091-7. PubMed ID: 19150091
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci.
Bastian PJ; Ellinger J; Wellmann A; Wernert N; Heukamp LC; Müller SC; von Ruecker A
Clin Cancer Res; 2005 Jun; 11(11):4097-106. PubMed ID: 15930345
[TBL] [Abstract][Full Text] [Related]
24. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
[TBL] [Abstract][Full Text] [Related]
25. Formamide as a denaturant for bisulfite conversion of genomic DNA: Bisulfite sequencing of the GSTPi and RARbeta2 genes of 43 formalin-fixed paraffin-embedded prostate cancer specimens.
Zon G; Barker MA; Kaur P; Groshen S; Jones LW; Imam SA; Boyd VL
Anal Biochem; 2009 Sep; 392(2):117-25. PubMed ID: 19505431
[TBL] [Abstract][Full Text] [Related]
26. [Circulating tumor cells and advanced prostate cancer].
Murez T; Droupy S; Rebillard X; Alix-Panabieres C
Bull Cancer; 2012 Jul; 99 Suppl 1():S4-15. PubMed ID: 22569300
[TBL] [Abstract][Full Text] [Related]
27. Detection of the circulating tumor cells in cancer patients.
Armakolas A; Panteleakou Z; Nezos A; Tsouma A; Skondra M; Lembessis P; Pissimissis N; Koutsilieris M
Future Oncol; 2010 Dec; 6(12):1849-56. PubMed ID: 21142859
[TBL] [Abstract][Full Text] [Related]
28. The potential use of cell-free-circulating-tumor DNA as a biomarker for prostate cancer.
He WS; Bishop KS
Expert Rev Mol Diagn; 2016 Aug; 16(8):839-52. PubMed ID: 27254598
[TBL] [Abstract][Full Text] [Related]
29. Methylated DNA for monitoring tumor growth and regression: how do we get there?
Kristiansen S; Nielsen D; Sölétormos G
Crit Rev Clin Lab Sci; 2014 Jun; 51(3):149-59. PubMed ID: 24611610
[TBL] [Abstract][Full Text] [Related]
30. [Circulating cell-free DNA as biomarker for cancer *header*].
Isomursu A; Kononen J; Kuopio T
Duodecim; 2015; 131(5):424-32. PubMed ID: 26237904
[TBL] [Abstract][Full Text] [Related]
31. Prostate cancer: Circulating tumour cells in prostate cancer.
Hille C; Pantel K
Nat Rev Urol; 2018 May; 15(5):265-266. PubMed ID: 29508846
[No Abstract] [Full Text] [Related]
32. TMEFF2: A Transmembrane Proteoglycan with Multifaceted Actions in Cancer and Disease.
Masood M; Grimm S; El-Bahrawy M; Yagüe E
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33371267
[TBL] [Abstract][Full Text] [Related]
33. Association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory prostate cancer.
Okegawa T; Nutahara K; Higashihara E
Int J Urol; 2010 May; 17(5):466-75. PubMed ID: 20337729
[TBL] [Abstract][Full Text] [Related]
34. The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer.
Ellinger J; Müller SC; Stadler TC; Jung A; von Ruecker A; Bastian PJ
Urol Oncol; 2011; 29(2):124-9. PubMed ID: 19762255
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
